newsfilter
← Earnings
Earnings Releases·

Amylyx Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $45.5 million ($0.38/share) for Q3 2026, widening from $34.4 million ($0.37/share) in the prior year period, driven by a $28.4 million R&D expense increase for the Phase 3 LUCIDITY trial.
  • Completed a public offering raising approximately $545 million, increasing cash, equivalents, and marketable securities to $768.1 million as of September 30, 2026.
  • Phase 3 LUCIDITY trial for avexitide met all primary and secondary endpoints, showing a 55% reduction in severe hypoglycemic events versus placebo with a favorable safety profile.
  • Maintains guidance to submit NDA for avexitide by end of 2026, targeting a potential commercial launch in 2027 contingent on approval, while advancing IND-enabling studies for AMX0318.
  • Solidified full commercial leadership team and launch readiness capabilities to support the anticipated 2027 avexitide commercialization.
Company
AMYLYX PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology